Patent 9526911 was granted and assigned to LaZure Scientific on December, 2016 by the United States Patent and Trademark Office.
Systems and methods for delivering electric fields to a target tissue of a patient for destruction of cancerous cells so as to elicit or induce a specific anti-cancerous cell immune response in the patient.